Table 1. Several experiments have demonstrated that CAR-T cells are characteristic of solid tumors .

Solid tumor	Antigen	Type of CAR-T cell	Property	conditions of research	Reference
Pancreatic cancer	Mesothelin	meso-CAR-T cell	Improved performance; increasing the effect time of engineered cells	In vivo	32
Breast cancer	HER2	HER2-CAR-T cell	Contains CD28 or 4-1BB signal range for functional activity	In vitro	33
Glioblastoma	HER2	CAR-T Cell that target HER2 and IL-13Rα2	Improving performance with sequential expression; Cytokine secretion	-	34
Non-Small Cell Lung Cancer	EGFR	CAR-T Cell that target EGFR	Without severe toxicity, high tolerance for the patient	clinical study	35
Neuroblastoma	GD2 CD171	CAR-T Cell that target GD2 CE7-CAR T	Increase the anti-tumor effect; With central nervous system toxicity (CNS) No out-of-target toxicity	In vivo In vivo	36 37
Liver	CEA	CEA CAR-T	No side effects of grade 3 or 4	clinical study	38
Head and neck cancer	ErbB	CAR-T Cell that target ErbB(T1E28z)	Ability to target multiple antigens	clinical study	39
Prostate cancer	PSMA	PSMA- CAR-T Cell :Negative TGF-β Receptor	Increased cytokine secretion, resistance to burnout, long shelf life	clinical study	40

HER2: human epidermal growth factor receptor 2; EGFR vIII: Epidermal growth factor receptor variant III; EGFR: Epidermal growth factor receptor; GD2: is a disialoganglioside expressed on tumors; CD171: neural cell adhesion molecule L1; CEA: Carcinoembryonic antigen; ErbB: family of receptor tyrosine kinases;

PSMA: prostate-specific membrane antigen.